| Bioactivity | SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models[1][2]. |
| Target | IC50: <5 nM (ALK); 1.87 nM (c-MET); 28.9 nM (AXL) |
| CAS | 1253286-90-6 |
| Formula | C26H25Cl2FN4O2 |
| Molar Mass | 515.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tian Y, et al., Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK. J Chem Inf Model. 2017 Apr 24;57(4):977-987. [2]. Li J, et al., Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors. ACS Med Chem Lett. 2013 Jul 12;4(8):806-10. |